InvestorsHub Logo
Followers 1
Posts 67
Boards Moderated 1
Alias Born 01/27/2020

Re: Kramrer post# 28169

Thursday, 04/30/2020 8:13:21 AM

Thursday, April 30, 2020 8:13:21 AM

Post# of 35961
"Inspyr, like Gilead’s Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment. Inspyr merged with Lewis and Clark Pharmaceuticals several years ago and since then has developed a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. Their pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RBSH News